Talk:New Article Requests

Before You Submit a Proposal

• EVALUATION CRITERIA: Review these to be sure your proposal is eligible. The current acceptance rate for new articles is approximately 41%.
• EXISTING ARTICLES: Review these to see if your proposed topic is already included or could be included in an existing EyeWiki article. You can do this by performing a thorough search using various related key terms.
  • If you find a pre-existing stand-alone article that addresses your topic or an article that includes your topic please edit the article to include your own input. You will be automatically recognized as a contributor to that article.
  • Of those proposals that are not accepted, 85% are rejected because the topic is already covered or could be covered in an existing EyeWiki article.
• PROPOSALS PREVIOUSLY SUBMITTED: Review these and please do not resubmit these topics. If there is substantial new evidence that has to come to light since the last proposal was rejected, you may resubmit a topic citing the new evidence to support a stand-alone EyeWiki article.
• PREAPPROVED TOPICS and ARTICLES NEEDING REVISION: Can't think of a topic for a new article? Consider revising topics on this list of articles flagged by the editorial board for revisions. Visit the discussion pages of these articles to find out what is needed. No approval is necessary to revise these articles. Currently, there are some new suggested topics that have been preapproved for stand-alone articles. Contact eyewiki@aao.org if you would like to work on one of the pre-approved new articles and can complete it within 30 days.

Instructions

• IMPORTANT: Review the section above "Before You Submit a Proposal"
• Click the "Add topic" link to create a new proposal on this page not in your own talk page.
• Then add the relevant list items as shown
  • Title: Enter this in the Subject field
  • Summary: Please provide some details about what will be covered and why you think the article would benefit EyeWiki. Do not submit a complete article.
  • Section: Indicate what subspecialty section the article should be added to. You may indicate up to 2 sections.
  • Submitted by: Name of the ophthalmologist submitting the proposal. Sign and date your request by entering 4 tilde ~ characters only. This will automatically add your username, a time stamp and a link to your profile. You will see this after you save the page.
    • SAMPLE: Rayna.Ungersma.AAO (talk) 10:01, April 30, 2024 (PDT)
• Click: SAVE at the bottom of the page

Sample Proposal

Biosimilars in Ophthalmology
Summary: Patents for original biologics used to treat nAMD and DME are approaching expiration. Numerous companies are striving to replicate these biologics as biosimilars, which are drugs that mimic the effects of the original biologic, but do not have the same active ingredients. This article will summarize the current literature about biosimilars and their safety, efficacy, and quality and provide an in-depth review of approved biosimilars as well as those that are in development. This article will provide EyeWiki readers with information about numerous alternatives for treatment nAMD and DME.
Section: Retina/Vitreous
Submitted by: Rayna.Ungersma.AAO (talk) 15:04, May 1, 2024 (PDT)

The Gut-Eye Axis

Summary: Recent studies underline a potential association between gut microbiota (GM) and ocular health. In this respect, some evidence supports the existence of a gut–eye axis involved in the pathogenesis of several ocular diseases, including age-related macular degeneration, uveitis, diabetic retinopathy, dry eye, and glaucoma. Therefore, understanding the link between the GM and these ocular disorders might be useful for the development of new therapeutic approaches, such as probiotics, prebiotics, symbiotics, or fecal microbiota transplantation through which the GM could be modulated, thus allowing better management of these diseases.

Section: Oncology/Pathology

Submitted by: Hashem.AbuSerhan (talk) 22:30, April 7, 2026 (PDT)

Persistent Ocular Hypertensive Viral Anterior Uveitis

A human ocular disease called persistent ocular hypertensive viral anterior uveitis (POH-VAU) has recently emerged, characterized by persistent ocular hypertension and inflammation that consistently tests negative for conventional viral pathogens (HSV, VZV, CMV, EBV, rubella). These cases present with atypical viral anterior uveitis patterns associated with novel zoonotic viral pathogens crossing species barriers. Covert mortality nodavirus (CMNV) from aquatic sources has been confirmed in ocular tissues and seroconversion in 70 patients with POH-VAU, with CMNV prevalent in farmed and wild aquatic animals worldwide (https://www.nature.com/articles/s41564-026-02266-x). Epidemiological analysis reveals that CMNV exposure frequency, severity, and number of exposures directly correlate with POH-VAU risk, with 71.4% of cases linked to unprotected processing of aquatic animals and consumption of raw aquatic products. While covert mortality nodavirus (CMNV) from aquatic sources has been identified as one causative agent, this represents a broader paradigm of emerging viral threats requiring expanded diagnostic considerations beyond traditional viral panels.

This article will provide practicing ophthalmologists with essential knowledge for recognizing, diagnosing, and managing these emerging viral uveitis entities when standard viral workups are negative. Key clinical features include recurrent anterior uveitis with persistent ocular hypertension, polymorphic keratic precipitates, and negative testing for typical ocular viruses. The article will cover differential diagnosis strategies when conventional viral etiologies are excluded, highlight unique epidemiological patterns including occupational exposures (aquaculture workers, seafood processors) and dietary risks (raw aquatic animal consumption), and provide guidance for expanded diagnostic approaches including novel viral testing. Given the potential for irreversible glaucomatous damage and the inadequacy of standard antiviral therapy, recognition of these emerging entities is crucial when patients present with "idiopathic" hypertensive anterior uveitis that fails to respond to conventional treatment approaches. This resource addresses a critical knowledge gap for the increasing number of cases that defy traditional viral uveitis classification.

Section: Uveitis

Submitted by: Bruce.B.Becker (talk) 16:47, April 9, 2026 (PDT)

Tissue plasminogen activator

Summary: Tissue plasminogen activator (tPA) is a fibrinolytic agent widely used in ophthalmology for the management of fibrin-related complications in both anterior and posterior segment conditions. It acts by converting plasminogen into plasmin, thereby promoting the degradation of fibrin membranes and clots, which helps restore aqueous flow, clear the visual axis, and improve surgical outcomes. Despite its broad and clinically valuable applications, this topic remains insufficiently covered in EyeWiki, highlighting the need for a comprehensive, evidence-based resource for clinicians. Clinically, tPA is utilized in a variety of settings, including severe fibrin reactions in endophthalmitis, toxic anterior segment syndrome (TASS), fibrinous anterior uveitis, fibrinous pupillary block, postoperative fibrin formation following cataract surgery or vitrectomy, subretinal hemorrrhage, and in the management of failed filtering blebs after glaucoma surgery; it may also be considered in selected cases of organized hyphema. Administration routes include intracameral, intravitreal, and subconjunctival injections, depending on the indication. Typical dosing ranges from 10–25 µg/0.1 mL for intracameral use and 25–50 µg/0.1 mL for intravitreal injection, with lower doses often used subconjunctivally for bleb-related indications, although variations exist based on clinical judgment. The drug is usually prepared from commercially available recombinant tPA (e.g., alteplase) under strict aseptic conditions and diluted with balanced salt solution to achieve the desired concentration, with prompt use recommended after preparation. Administration techniques follow standard sterile ophthalmic injection protocols, with careful attention to dose accuracy. While generally effective and well tolerated, potential complications include transient intraocular pressure fluctuations, hyphema, corneal endothelial toxicity (rare), and intraocular hemorrhage, particularly at higher doses, underscoring the importance of appropriate patient selection and dosing.

Section: Retina/Vitreous

Submitted by: Hashem.AbuSerhan (talk) 00:51, April 10, 2026 (PDT)

Drug-induced Nystagmus

Summary: Data on drug-induced nystagmus prevalence remain scarce and are largely limited to case series and case reports. This article provides a detailed description of different types of nystagmus caused by drugs including anti-epileptics, sedatives and psychoactive medications, lithium, antiarrhythmics and antibiotics. We include multiple charts for quick reference. Section: Neuro-ophthalmology Submitted by: Eugenia Ramos Eugenia.Ramos (talk) 14:07, April 11, 2026 (PDT)